Skip to main content



Dr. Mehdi Moezi is board-certified in medical oncology, hematology, and internal medicine, and practices at our Fleming Island location. Originally from Iran, Dr. Moezi earned his Doctor of Medicine from the University of Tehran before completing his residency and fellowship programs in New York. He began his practice in 1990 at SUNY Downstate in Brooklyn New York, where he spent 10 years researching with some of the world’s leaders in lymphoma and myeloma. Dr. Moezi and his family settled in North Florida in 2001, when he began practicing at CSNF.

As the Chair of the CSNF’s Clinical Research Committee, Dr. Moezi understands and appreciates the way clinical research and trials have changed the way cancer is diagnosed, understood, and treated – especially within the last decade. “I have participated in many clinical trials, and the outcome of some of this research has changed the standard of care for treating malignancies,” he says. Dr. Moezi has also had the privilege of actively participating in the design of clinical trials that help find new treatment options for cancer patients.

Aside from the clinical research program, Dr. Moezi enjoys the “teamwork, excellent co-workers, and comprehensive care” that serve as the foundation of CSNF.

When not in the office, Dr. Moezi enjoys spending time with his wife and two grown children, and enjoys performance arts, music, reading, traveling, skiing, tennis, and museums.

Curriculum Vitae


Internal Medicine


Medical Oncology


European Society of Medical Oncology

Florida Medical Association

Florida Society of Clinical Oncology

American Society of Clinical Oncology

American Society of Hematology

American Medical Association

American College of Physicians


State University of New York Downstate Medical Center



Interfaith Medical Center


Tehran University Hospitals


University of Tehran, School of Medicine

Doctor of Medicine


2007- Present

Phase I Cancer Research Program, ICON-FOA, Director

2006- Present

FLASCO Ad hoc Committee on Clinical Trial Network

2002- Present

Research Committee in Cancer Specialists of North Florida, Member


FLASCO Clinical Practice Committee , Member

2004- 2005

Infection Control Committee Putnam Community Medical Center, Chair

2004- 2005

Clinical Quality Council Putnam Community Medical Center, Member


Medical Performance Improvement Committee, Putnam Community Medical Center, Member


CCU/ICU Committee Putnam Community Medical Center, Member


Millennium Oncology Consultant Meeting-Velcade and Multiple Myeloma


Astra Zeneca Advisory Committee - Hormone Therapy for Breast Cancer


Internet Advisory Committee, Zometa for Treatment of Multiple Myeloma and Metastatic Bone Disease. Novartis. Conducted by Dr. James Berenson.


Advisory Committee - Targeted Therapy, New Approach to Cancer Medicine. Novartis


Advisory Committee, Neumega – Thrombocytopenia in Chemotherapy Patients. Wyeth Oncology.

RESEARCH (Principal Investigator Responsibilities)


A randomized, multicenter, open-label Study of VELCADE with Rituximab or Rituximab alone in subjects with relapsed or refractory follicular Non-Hodgkin's B-cell lymphoma. Phase III, Interventional


AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer. Phase I/II, Interventional


Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma. Phase II, Interventional


Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma. Phase III, Interventional


A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC. Phase II, Interventional


SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial. Phase II, Interventional


An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only. Phase II, Interventional


Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer. Phase II, Interventional


A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion. Phase III, Interventional


Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy. Phase III, Interventional


Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE). Phase III, Interventional


A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy. Phase III, Interventional


A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011). Phase III, Interventional


Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma Phase III, Interventional


A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2). Phase III, Interventional


Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer. Phase III, Interventional


A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma. Phase III, Interventional


Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Phase III, Interventional


Blood Journal

Incidence, Clinical Profile and Outcome of Patients with Deep Vein Thrombosis and Pulmonary Embolism at a Community Hospital

Blood Journal

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma after Prior Rituximab

Journal of Clinical Oncology

Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy.

Journal of Clinical Oncology

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study

Blood Journal

A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib

Blood Journal

A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib

Blood Journal

A New Multinational Observational Study in Multiple Myeloma: Initial Report of the PREAMBLE Study

Lung Cancer

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoxlax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).

Journal of Clinical Oncology

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer.

Journal of Clinical Oncology

A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).